Acomplia is the brand name of the medication while Rimonabant is the name of its active ingredient. Acomplia (Rimonabant), after its launch in the June 2006, has conquered a vast portion of weight loss drug market. This success of Rimonabant is the result of the benefits which it has given to numerous obese individuals in the European countries. After the UK, presently several other European countries are taking the benefits of Acomplia. Germany, Norway, Denmark, Ireland, Finland and Austria are those European nations where Sanofi-Aventis has already launched the sale of Rimonabant pills.

Rimonabant blocks the working of cannabinoid receptor type-1. This function of Rimonabant pill has great significance in control of appetite. Cannabinoid type-1 (CB-1) receptors are the messengers of coordination system of the human body. Their working enables the brain to know about various requirements of cells. Excess urge for food and urge for smoking are two harmful signals, which CB-1 receptors transfer to the brain. Regular use of Rimonabant pill keeps working of CB-1 receptors in control. The process not only controls excess urge for food but also the urge for smoking.

Diet pill Acomplia (Rimonabant) is available in two different volumes i.e. 10mg and 20mg. The general prescription volume of Rimonabant Acomplia is 20mg. In clinical tests and usages this volume of the medication is found to be very effective in control of appetite. This medication controls appetite efficiently only when taken on an empty stomach. An hour before breakfast is the ideal time to take Rimonabant diet pills. Swallow the pill of prescribed volume with a glassful of plain water daily. Try not to miss any dose, but if happens so; never try to compensate it by overdosing. Overdosing Rimonabant can be harmful for your health.